Category Archives: Most Popular

Apple Inc. (AAPL) iPhone Sales Still Growing; FBR Capital and Bernstein Still Bullish

407263.jpg

Apple (NASDAQ: AAPL) fans have been engrossed with the new Apple Watch, but Apple investors are still excited by iPhone 6 sales growth, specifically in China. Looking back at the first quarter of 2015, Apple CFO confirmed that Apple sold

Top-Ranked Analysts Are Bullish on Gilead Sciences, Inc. (GILD)

406355.jpg

By Sarah Roden Gilead Sciences (NASDAQ: GILD) has been a favorite among biotech investors due to its successful hepatitis C therapies; Harvoni and Sovaldi. However, the biopharmaceutical company is making headlines again with a new drug for gastric cancer; GS-5745.

Analysts Share Expectations Ahead Of Alibaba Group Holding Ltd Earnings

Analysts have been buzzing with anticipation over Alibaba’s (NYSE: BABA) upcoming earnings report, scheduled to be released tomorrow before market open. This report will be Alibaba’s third earnings report as a public company. Alibaba shares last closed at $80, just

Apple Inc. Never Fails to Impress; Analysts Cheer

396339.jpg

Sarah Roden Apple Inc. (NASDAQ: AAPL) released another record-breaking earnings report. The hegemonic technology company posted record second quarter results on April 27, beating all estimates. Despite inevitable sequential declines due to last quarter’s release of the iPhone 6/6 Plus,

Analysts Bullish on Facebook Inc Despite Missed Revenue

395674.jpg

Facebook Inc (NASDAQ: FB) released first quarter earnings for 2015 on April 22. The social media giant missed revenue estimates for the first time, pointing to strong foreign exchange headwinds. Highlights of the earnings report include revenue of $3.543 billion,

Analysts Provide Update for Biogen, PTC Therapeutics, GW Pharma, and Isis Pharma In Light Of AAN Meeting

By Sarah Roden The American Association of Neurology is hosting its annual meeting this week in Washington, DC. Through the end of this week, major biotechnology companies will be making presentations highlighting drug breakthroughs and updates. Analysts at Cowen &